A Phase II Study of Atezolizumab Immunotherapy plus Bevacizumab for Patients with Metastatic Urothelial Cancer Who Cannot Have Cisplatin-Based Chemotherapy

Print

Full Title

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer

Purpose

The standard treatment for metastatic urothelial cancer, including bladder cancer, is cisplatin chemotherapy. But not all patients are strong or healthy enough to receive this treatment. The purpose of this study is to assess the safety and effectiveness of atezolizumab immunotherapy plus the drug bevacizumab in patients with metastatic bladder cancer who cannot receive cisplatin treatment.

Atezolizumab boosts the power of the immune system to find and kill cancer cells. Bevacizumab works by blocking the development of the blood vessels that tumors need to receive nourishment and spread. Both drugs are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced urothelial cancer (cancer of the renal pelvis, ureter, bladder or urethra) and be ineligible to receive cisplatin.
  • Patients may not have previously received immunotherapy.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Samuel Funt at 646-888-4770.

Protocol

18-275

Phase

II

Investigator

Co-Investigators